D2 assists emerging and established pharmaceutical, biopharmaceutical and medical device manufacturers to develop and execute strategic business initiatives, ensuring successful launch, distribution and reimbursement to support an ongoing leadership position in the marketplace. D2’s reach includes the US, Canada, Puerto Rico and over 20 European markets.
Emerging companies are faced with multiple challenges in taking their products from the clinical phase to commercialization. This process can be daunting and, often times, these organizations lack the experience, established business infrastructure and human resources to successfully commercialize their product(s). D2 brings strategic expertise and tactical support to ensure our clients execute a successful launch, in addition to providing post launch and ongoing support.
The ongoing evolution of the bio/pharma marketplace, as well as the increasing complexity of product portfolios and distribution models, require established/mature companies to continually assess and improve business processes. Increasingly, issues impacting pharmaceutical organizations, including Wall Street pressures, Patent expirations and R& D challenges, as well as market pressures such as government mandates (pedigree/state licensing), trading partners such as wholesalers, and third party payors mandates, are all converging on bio/pharma manufacturers. Our team’s broad base of knowledge ensures that our clients receive “best practice” advice in all phases of commercialization.
D2 has extensive experience for other entities that touch the pharma/biotech industries, such as specialty pharmacies, wholesale distributors, group purchasing organizations and others.
In addition, D2 works with a consulting consortium to provide solutions across the necessary disciplines to drive commercial results.
© 2017 D2 Pharma Consulting LLC. All Rights Reserved